Dale J. Hu, Jian Xing, Rania A. Tohme, Youlian Liao, Henry Pollack, John W. Ward, Scott D. Holmberg – 28 January 2013 – Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009‐2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S.

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Jaime Bosch – 28 January 2013

Richard J. Aspinall – 28 January 2013

Paul J. Pockros, Donald Jensen, Naoky Tsai, Ryan Taylor, Alnoor Ramji, Curtis Cooper, Rolland Dickson, Alan Tice, Rohit Kulkarni, John M. Vierling, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the JUMP‐C Investigators – 28 January 2013 – Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA‐dependent RNA polymerase, with activity across all HCV genotypes.

Zi Yin, Chao Liu, Yajin Chen, Yu Bai, Changzhen Shang, Rongyan Yin, Dong Yin, Jie Wang – 28 January 2013 – The optimal surgical strategy for treatment of patients with synchronous colorectal liver metastases (SCLRM) remains controversial. We conducted a systematic review and meta‐analysis of all observational studies to define the safety and efficacy of simultaneous versus delayed resection of the colon and liver. A search for all major databases and relevant journals from inception to April 2012 without restriction on languages or regions was performed.

R. Scott Rector, E. Matthew Morris, Suzanne Ridenhour, Grace M. Meers, Fong‐Fu Hsu, John Turk, Jamal A. Ibdah – 28 January 2013 – Earlier reports suggest a link between mitochondrial dysfunction and development of hepatic insulin resistance. Here we used a murine model heterozygous (HET) for a mitochondrial trifunctional protein (MTP) gene defect to determine if a primary defect in mitochondrial long‐chain fatty acid oxidation disrupts hepatic insulin action.

Monika Ferlitsch, Markus Peck‐Radosavljevic, Arnulf Ferlitsch – 28 January 2013

Jing Hieng Ngu, Richard Blair Gearry, Chris Miles Frampton, Catherine A.M. Stedman – 28 January 2013 – Autoimmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death. We aimed to identify predictors of advanced liver fibrosis at presentation, predictors of incomplete response to initial immunosuppression, and predictors of poor liver‐related outcomes in the population‐based AIH cohort from Canterbury, New Zealand. Cases diagnosed after 1980 that fulfilled standard diagnostic criteria were included.

Jessica A. Davila, Jennifer R. Kramer, Zhigang Duan, Peter A. Richardson, Gia L. Tyson, Yvonne H. Sada, Fasiha Kanwal, Hashem B. El‐Serag – 28 January 2013 – The delivery of treatment for hepatocellular carcinoma (HCC) could be influenced by the place of HCC diagnosis (hospitalization versus outpatient), subspecialty referral following diagnosis, as well as physician and facility factors. We conducted a study to examine the effect of patient and nonpatient factors on the place of HCC diagnosis, referral, and treatment in Veterans Administration (VA) hospitals in the United States.